[1] Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850. [2] 戴宜武,王振光,秦家振. 脑胶质瘤治疗进展[J]. 中华临床医师杂志:电子版,2013,7(14):6225-6228.[3] Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166-193.[4] Beier CP, Beier D. CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed). 2011;3:701-710.[5] Lin KC, Park HW, Guan KL, et al. Regulation of the Hippo Pathway Transcription Factor TEAD. Trends Biochem Sci. 2017;42(11):862-872.[6] Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6): 642-656.[7] Lian I, Kim J, Okazawa H, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24(11):1106-1118.[8] Maugeri-Saccà M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 2016;99:115-122.[9] 吴艳林,蔡政,张明智,等. 双氢青蒿素抑制胶质瘤干细胞侵袭迁移的机制[J]. 中国组织工程研究,2016,20(6):765-770.[10] 刘义锋,张保朝,温昌明,等. 槲皮素通过STAT通路抑制胶质瘤干细胞增殖促进其凋亡[J]. 中国组织工程研究,2017,38(5): 657-662.[11] Morgan LL. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2015;17(4):623-624.[12] Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl_5):v1-v75.[13] Wang Z, Terakawa Y, Goto H, et al. Glioblastoma in long-term survivors of acute lymphoblastic leukemia: Report of two cases. Pediatr Int. 2016;58(6):520-523.[14] Linet MS, Kim KP, Rajaraman P. Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr Radiol. 2009;39 Suppl 1:S4-26.[15] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016,96(7):485-509.[16] 孙增峰,李文良,谷峰,等. 胶质瘤耐药相关机制的研究进展[J]. 中华肿瘤防治杂志,2011,18(7):551-556.[17] Wang L, Zhang L, Shen W, et al. High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas. Exp Ther Med. 2016;11(2):571-576.[18] Watt KI, Harvey KF, Gregorevic P. Regulation of Tissue Growth by the Mammalian Hippo Signaling Pathway. Front Physiol. 2017;8:942.[19] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418): 61-70.[20] He J, Bao Q, Yan M, et al. The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease. Br J Pharmacol. 2017 Apr 3. [Epub ahead of print][21] Zhang Y, Del Re DP. A growing role for the Hippo signaling pathway in the heart. J Mol Med (Berl). 2017;95(5):465-472.[22] Hong AW, Meng Z, Guan KL.The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol. 2016;13(6):324-337.[23] Patel SH, Camargo FD, Yimlamai D. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. Gastroenterology. 2017;152(3):533-545.[24] Tamm C, Böwer N, Annerén C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J Cell Sci. 2011;124(Pt 7):1136-1144.[25] Lian I, Kim J, Okazawa H, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24(11):1106-1118.[26] Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759-772.[27] Li YW, Shen H, Frangou C, et al. Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle. 2015;14(1):146-156.[28] Chang C, Goel HL, Gao H, et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells. Genes Dev. 2015;29(1):1-6.[29] Noto A, De Vitis C, Pisanu ME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. 2017;36(32):4573-4584.[30] Bora-Singhal N, Nguyen J, Schaal C, et al. YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells. Stem Cells. 2015;33(6):1705-1718.[31] Tanaka K, Osada H, Murakami-Tonami Y, et al. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215-224.[32] Bhat KP, Salazar KL, Balasubramaniyan V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011;25(24): 2594-2609.[33] Xia Y, Zhang YL, Yu C, et al. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One. 2014;9(11):e109575.[34] Khoshnevisan A. An overview of therapeutic approaches to brain tumor stem cells. Med J Islam Repub Iran. 2012;26(1): 31-40.[35] Zhu J, Wang H, Ji X, et al. Differential Nrf2 expression between glioma stem cells and non-stem-like cells in glioblastoma. Oncol Lett. 2014;7(3):693-698. |